Healthcare Policy, Market Access

Gender Mainstreaming in Policy Making: An Overlooked Approach in Healthcare and Pharma?

Gender Mainstreaming in Policy Making: an Overlooked Approach in Healthcare and Pharma?While we all recognise the biological differences between women and men, healthcare hasn’t always been viewed through a gender lens. This is changing in more advanced markets like the UK, the Nordics, and Canada, which have started to mainstream gender in their healthcare policy-making procedures, but it is often non-existent in developing or under-developed countries where the health gap hits most.

So What Is Gender Mainstreaming in Healthcare?
Gender mainstreaming refers to the process of evaluating the impact and implications on both women and men of any / all levels of policy-making from planning and implementation, to monitoring and evaluation.

Mortality and morbidity data show a discrepancy between women and men’s health status and a difference in healthcare utilization and access, preventative healthcare use, and health seeking behaviours. For example, women’s life expectancy is higher than men’s; however, women live longer in disability. To give another example, men access primary care and utilize preventive care less than women.

Some of the differences are attributed to the different biological functions of females and males. Other undermined reasons are linked to the social roles and the impact of social determinants of health (such as labour, education, economic status and culture) on women and men. Failing to respond to the latter factors leads to gender inequities in healthcare, a concept that policy makers are increasingly wary about, and keen to eliminate.

While there is no clear evidence that directly links engendered healthcare systems to improved healthcare outcomes, research shows that healthcare systems responsive to gender inequities scored better service delivery and increased patients’ satisfaction.

Gender mainstreaming efforts vary between countries and healthcare systems. Devising a gender policy depends on the baseline that the country’s healthcare is at. Pre-requisites are necessary for successful gender mainstreaming to take effect. Top-down and bottom-up efforts are equally crucial to achieve gender sensitivity.

Pharma’s Changing Gender Focus
In the pharmaceutical arena, the sector stood accused for many years of prioritising research into “male” diseases, and that areas such as contraception focused only on women, not men. However, over the last ten years or so, dramatic advances have been made in many areas of female health, notably cervical and breast cancer, and several pharmaceutical companies now have whole divisions devoted towards female health.

Nevertheless, in some parts of the world and in less developed societies, women face additional barriers to access of pharmaceuticals. The discrepancy stems from cultural norms, for example son preferences are still widely apparent in East Asian societies like India. Little has been done from the pharma’s side to tackle gender inequities in medicine access.

A Growing Need
There is a growing need in healthcare to study the relationship between gender differences and the interaction between women and men, and healthcare systems. Assessing the impact on gender is especially important amid healthcare reform and when designing a healthcare intervention or prevention program.

In general, more advanced markets are beginning to acknowledge the importance of gender in healthcare. Squeezed public investments in healthcare will continue to go in a more gender-responsive direction looking for systems efficiency gains and personalized healthcare. Implications on pharmaceuticals’ R&D and reimbursement decisions go hand in hand.

About Farah Ramadan

Farah Ramadan is an analyst within the IHS Healthcare & Pharma practice. She is involved in production and analysis both for existing and new products, as well as multi client studies. Farah holds a Masters in International Health Management from Imperial College, UK, and has experience in statistics production and dissemination. She specializes in healthcare policy and emerging markets.


2 thoughts on “Gender Mainstreaming in Policy Making: An Overlooked Approach in Healthcare and Pharma?

  1. Great post Farah! Very well written – there’s definitely a need to increase awareness of the role of gender norms, values, and inequality in health care. However, these differences in gender evolve over time, and are ever changing. So the good news is that the poor health consequences resulting from gender inequalities in various places are not static and healthcare systems can be shaped, like you state, through policy-making procedures.
    Looking forward for your next post!

    Posted by Anonymous | January 26, 2012, 7:55 am
  2. Thank you so much for your comments – keep reading!

    Posted by Farah Ramadan | January 30, 2012, 5:16 am

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter


Get every new post delivered to your Inbox.

Join 332 other followers